Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitorsWataru Fukuokaya, Shin Egawa, Naoki Terada et al.|Urologic Oncology Seminars and Original Investigations|2022Cited by 24
Clinical benefit of continuing pembrolizumab treatment beyond progression in patients with metastatic urothelial carcinomaWataru Fukuokaya, Shin Egawa, Takahiro Kimura et al.|Cancer Immunology Immunotherapy|2021Cited by 11
Comparison of the Immunotherapy Response Evaluation Criteria in Solid Tumours (iRECIST) with RECIST for capturing treatment response of patients with metastatic urothelial carcinoma treated with pembrolizumabWataru Fukuokaya, Shin Egawa, Takahiro Kimura et al.|British Journal of Urology|2020Cited by 6
Impact of Dose-Effect in Smoking on the Effectiveness of Pembrolizumab in Patients with Metastatic Urothelial CarcinomaWataru Fukuokaya, Shin Egawa, Takahiro Kimura et al.|Targeted Oncology|2021Cited by 6
Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinomaWataru Fukuokaya, Takahiro Kimura, Takafumi Yanagisawa et al.|Cancer Immunology Immunotherapy|2022Cited by 5